Physician profile

Darlene Clemente

Obstetrics & Gynecology · W Paterson, NJ

NPI 1336222132

$349.49

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$139.48

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Mayne Pharma Commercial LLC $90.34 2021-2023
Abbvie INC. $66.63 2021-2023
Astellas Pharma US INC $44.28 2023-2024 Veozah
Daiichi Sankyo INC. $37.68 2022
Exeltis, USA INC. $31.21 2021-2024 Slynd
Roche Diagnostics Corporation $23.24 2021
Organon LLC $17.50 2023 Jada System
Glaxosmithkline, LLC. $13.38 2022
Agile Therapeutics, INC. $13.27 2022
Evofem Biosciences, INC. $11.96 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Darlene Clemente

$349.49

in general payments reported 2019-2025

Years
2021-2024
Top company
Mayne Pharma Commercial LLC

https://glasscript.com/doctor/571808/darlene-clemente

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.